R/R MM: HDAC inhibitor achieves response in combination with bortezomib and dexamethasone

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Ricolinostat 160 mg/d in combination with bortezomib and dexamethasone was well tolerated and delivered promising efficacy in patients with relapsed/refractory (R/R) multiple myeloma (MM).

Why this matters

  • Resistance to proteasome inhibition is inevitable leading to disease pr...